Kornimate/medical-research-clean huggingface dataset:
determination of the aneurysm vulnerability index by stimulation and medical imaging

Conditions: Aneurysm

Summary: stroke is the leading cause of disability in france with 130,000 cases per year, 20% of strokes being hemorrhagic, with a majority of intracranial aneurysm rupture (80%). each year, 6000 meningeal hemorrhages (mha) caused by cerebral aneurysm rupture are reported in france: 40% of patients die within the first month and 30% are left with severe and permanent disability. intracranial aneurysms are present in 2 to 6% of the population and only about 0.5% of them will rupture. given the human and economic costs associated with this disease, systematic medical screening for intracranial aneurysms could be useful. however, the operative risk of endovascular treatment remains non-zero (around 1%) and could be proposed only to a selected population of aneurysms at risk of rupture. the absence of diagnostic criteria for aneurysmal vulnerability does not allow for the moment to consider screening for this disease, which continues to strike without warning a young and active population. nevertheless, access to brain imaging allows the detection of an increasing number of intracranial aneurysms. the question of preventive treatment then arises and is still a difficult point discussed by neurosurgeons / neurointerventionists based on general epidemiological data difficult to apply to an individual.


Eligibility criteria:
inclusion criteria: * age limits to \> 18 years * collection of the informed consent (patient or legal representant) * affiliation or recipient with the mode of social security - groupe anévrysme rompu * patient porteur d'un anévrysme rompu - groupe anévrysme non rompu * patient porteur d'un anévrysme non rompu exclusion criteria: * subject presenting contraindications in mri (ferromagnetic foreign bodies, pace-maker ...) * claustrophobia * women pregnant or breast-feeding * patient participating in an other study * patient have participated in a study in the 3 months before the inclusion * in period of exclusion relative to another protocol * person with majority age protected by the law (supervision or trusteeship). * patient not reading the french language * patient or representant for whom it impossible to give accurate informations

Keywords: aneurysm
aquesys xen 45 glaucoma implant in refractory glaucoma

Conditions: Glaucoma; Glaucoma, Open Angle

Summary: to establish the safety and performance of the aquesys xen 45 glaucoma implant in eyes with refractory glaucoma.

a prospective, multi-center, single arm, open-label clinical trial to evaluate the safety and iop lowering performance of the aquesys xen 45 glaucoma implant in refractory glaucoma patients.

Eligibility criteria:
inclusion criteria: * diagnosis of refractory glaucoma * maximally-tolerated medicated iop at two preoperative visits of ≥20 mmhg and ≤35 mmhg * visual field mean deviation score of -3 db or worse * shaffer angle grade ≥ 3 * area of free, healthy and mobile conjunctiva in the targeted quadrant exclusion criteria: * active neovascular glaucoma * previous glaucoma shunt/valve in the targeted quadrant * history of corneal surgery, opacities or disease/pathology * anticipated need for ocular surgery * non-study eye with bcva of 20/200 or worse

Keywords: glaucoma implant trabeculectomy poag primary open angle glaucoma pseudoexfoliation glaucoma pigmentary glaucoma
overactive bladder (oab) drink advice study

Conditions: Overactive Bladder Syndrome

Summary: the researchers want to investigate how fluid intake influences the symptoms of oab. the researchers will recruit 45 patients with oab and randomize them (blind) in 3 groups (low/normal/high fluid intake). patients will follow this drink pattern for 2-5 days, while filling in an standard micturation diary for 2 days. this micturation diary is coupled to: collection of multiple urine samples, urine ph measurements, and a perception of intensity of urgency scale (ppius) scoring table. all this is collected by the patients themselves. urine samples will be analysed for osmolality by the clinical chemistry department.


Eligibility criteria:
inclusion criteria: * oab patients exclusion criteria: * benign prostatic hyperplasia * neurogenic detrusor overactivity * urine tract infection * anticholinergics * intravesical botulin toxin * cardiac failure * renal insufficiency * sacral neurostimulation * percutaneous neurostimulation

Keywords: oab urine osmolality urge fluid intake ppius urge score bladder
predictors of improvement and deterioration of community acquired pneumonia in children

Conditions: Predictors of Improvement and Deterioration of Community Acquired Pneumonia

Summary: predictors of improvement and deterioration of community acquired pneumonia in children community-acquired pneumonia (cap) is the most prevalent respiratory infectious disease. it is defined as an acute infection of the lung parenchyma that is acquired outside the hospital. community-acquired pneumonia (cap) is one of the most common disorders faced in clinical practice . \[1,2\] childhood cap is the leading cause of death in children younger than five years globally\[3\] . acute phase reactants (apr) are inflammatory mediators that show significant alternations in serum levels in response to inflammation, these markers are responsible for some adverse effects such as anorexia, fever, fatigue, and anemia of chronic illness \[4\] apr can be applied for the assessment of disease severity in cap in collaboration with clinical evaluation and pneumonia severity scores \[5\]. the most common apr are (nlr), crp, and esr, changes in the level of these indices can be used in the diagnosis and prognosis of inflammatory and infectious diseases \[5\] nlr is a rapid, simple, and cheap maker of the systemic inflammatory process, it is calculated as the ratio between neutrophil count to lymphocyte count from peripheral blood sample. numerous researches have assessed the role of nlr in many infectious diseases such as sepsis, bacteremia, and septic shock, in addition, it can predict the severity and outcome of cap \[6\] crp is one of the best indicators of the acute phase response to inflammation. this serum protein is synthesized by hepatocytes and is classified as an acute-phase protein based on its increased serum concentration during inflammation and infection\[7\] so, the aim of the current study was to assess levels of apr such as total leucocytic count (tlc), platelets, neutrophils, neutrophils-to-lymphocyte ratio (nlr), crp, d-dimer, ferritin, and esr in patients with cap (as a primary outcome) and to correlate between their measured values and disease severity (as a secondary outcome)

assessment of community-acquired pneumonia (cap) severity in association with various pneumonia severity scores. so, the aim of the study was to assess levels of apr such as total leucocytic count (tlc), platelets, neutrophils, neutrophils-to-lymphocyte ratio (nlr), crp, d-dimer, ferritin, and esr in patients with cap and to correlate between their values and disease severity.

Eligibility criteria:
inclusion criteria all patients above a month and below 18 years old, both sexes, fulfilling diagnosis of cap exclusion criteria: * non-pulmonary infections, liver, renal, and cardiac diseases.and neonates with age less than a month
bladder scan of residual urine with new catheter

Conditions: Urinary Incontinence

Summary: male intermittent catheters (ics) range from 340-500 mm long, with the european standard minimum length being 360 mm for a catheter without a balloon and 275 mm for one with a balloon. this length is defined by hospital standards although it is known that the male urethra has an approximate maximum length of 29 cma new intermittent catheter developed by coloplast a/s is a 30-cm-long sterile, ready-to-use, hydrophilic-coated male catheter. there is a lack of clinical data documenting that male ics that are shorter and more or less flexible than standard catheters can sufficiently empty the bladder of male subjects. this will be tested using ultrasound to measure residual urine in the bladder following catheterisation with new product and standard length catheter.

see brief summary

Eligibility criteria:
inclusion criteria: 1. subject is a male ic user able to self-catheterise 2. subject has used hydrophilic-coated ics for at least 1 month 3. subject is at least 18 years old. 4. subject has provided informed consent. exclusion criteria: 1. subject has symptoms of uti (ie, fever, autonomic dysreflexia, spasticity, discomfort or pain over the kidney or bladder, onset/increase in incontinence episodes, cloudy urine with increased odour, malaise, lethargy, or sense of unease). 2. subject has known abnormalities in the lower urinary tract.
effect of vitamin e-containing dressing on surgical site infection in colorectal surgery

Conditions: Surgical Site Infection

Summary: a prospective, randomized study will be performed. patients are randomized using a 1:1 allocation into 2 groups: patients receiving a vitamin e-containing dressing (group 1) and a conventional dressing (group 2). the primary outcomes variable will be occurrence of incisional ssi. follow-up will be 30 days postoperatively.

a prospective, randomized study will be performed. patients are randomized using a random number table into 1:1 allocation into 2 groups: patients receiving a vitamin e-containing dressing (group 1) and a conventional dressing (group 2). in group 1 the wound will be covered with a vitamin e embebbed gauze and plastic adhesive tape. in group 2, , the wound will be covered with standard gauze and plastic adhesive tape. the primary outcomes variable will be occurrence of incisional ssi, defined by cdc criteria. follow-up will be 30 days postoperatively.

Eligibility criteria:
inclusion criteria: * diagnosis of colorectal neoplasms * plan to undergo an elective operation with curative aims * laparoscopic surgery exclusion criteria: * anastomotic leak * lost to 30-days follow-up
effect of exercise as non-surgical treatments on time to total hip replacement surgery

Conditions: Osteoarthritis

Summary: the aim of this trial is to test the hypothesis that patients with severe hip osteoarthritis postpone time to hip replacement surgery following participation in a patient education and supervised exercise program when compared to patients receiving patient education alone.

hip replacements are performed at an increasing rate, also in younger and less disabled patients. recent studies indicate non-surgical interventions being effective in reducing pain and disability also at later stages of disease when hip replacement is considered. possible, non-surgical treatments can be used to postpone hip replacement. the effect of education and supervised exercise on time to hip replacement is largely unknown

Eligibility criteria:
inclusion criteria: * 40 years and older * indication for total hip arthroplasty * residency within local municipal or willing to commute exclusion criteria: * inflammatory joint disease * earlier ipsilateral proximal femur fracture * hip pain \< 3 months * neuropathy or neuromuscular disease * malignant disease * diseases where a moderate level of physical exercise is contraindicated * unable to speak or read danish * unable to participate for other reasons * refuse to participate

Keywords: exercise therapy education osteoarthritis hip hip replacement
visualization of coronary artery disease for modification of risk factors

Conditions: Coronary Artery Disease; Non-Obstructive Coronary Atherosclerosis

Summary: the vicad-risk study assesses if visualization of coronary ct angiography (cta) images in participants with non-obstructive coronary artery disease will improve ldl lowering, reduce reporting of side effects by cholesterol lowering medications, and modify the coronary artery disease phenotype over 12 months.

in denmark non-obstructive coronary artery disease is found in 35-40% of patients undergoing coronary ct angiography for suspected coronary artery disease. modification of risk factors is essential in patients with coronary artery disease to prevent major cardiovascular events. however, in non-obstructive coronary artery disease, initiation and adherence to treatment with lipid lowering therapy is poor. the study will include 273 patients from 5 different sites; patients will be randomized into 3 groups; standard follow up by general practice, structured disease education or the combination of the latter with visualization of coronary ct angiography images. a follow-up ct angiography will be performed at 12 months.

Eligibility criteria:
inclusion criteria: * new diagnosis of nonobstructive coronary artery disease * no known coronary artery disease (no previous coronary revascularization) * cad-rads score 1-3 * ldl cholesterol \> 2.0 mmol/l * life expectancy \>3 years * signed informed consent exclusion criteria: * post cta test indication for invasive coronary angiography * non-evaluable cta exam * obstructive coronary disease (one or more coronary stenosis ≥70%, left main \>40%) * ongoing lipid lowering medical treatment (patients already on lipid lowering medical therapy can be included if the treatment was initiated \<3 months before the time of the cta test) * bmi \>40 * renal insufficiency (egfr \<40 ml/min) * allergy to iodinated contrast media * contraindications to statins (active liver disease child-pugh a, b and c, excessive alcohol consumption) * participation in a cardiac rehabilitation or lifestyle modification program * pregnancy

Keywords: coronary computed tomography hypercholesterolemia
ultrasound-enhanced uptake of chemotherapy in patients with inoperable pancreatic ductal adenocarcinoma

Conditions: Carcinoma, Pancreatic Ductal

Summary: patients with inoperable pancreatic cancer have extremely poor prognosis with five year survival below 8% in norway. life-prolonging chemotherapy has very limited effect, but is the only therapeutic option for these patients. this tumor is characterized by poor uptake and chemoresistance. toxic effects on healthy tissue restrict doses applied and maintenance of treatment intensity. this severely limits clinical outcome. increasing the local uptake of chemotherapy has potential benefits for patients in connection to side effects, survival and possible cure. treatment with focused ultrasound (fus) combined with microbubbles (mbs) is proved promising to improve treatment response in animal and clinical trials. ultrasound can induce biological effects deep inside the body without surgical intervention. this opens for local delivery of drugs at desired sites. fus in combination with regular contrast mbs has been reported to influence the delivery of drugs to tumors. in this trial fus and mb will be applied to locally advanced pancreatic cancers shortly after the administration of conventional chemotherapy. primary aim of the trial is to investigate whether the effect of the cytostatic drug, measured in tumor volume, can be increased.


Eligibility criteria:
inclusion criteria: * radiologically verified stage iii or iv pdac or medically inoperable stage iib t3 pdac * eligible for 1st line treatment with folfirinox, gemcitabine -nab paclitaxel, or gemcitabine monotherapy. * ecog 0 - 1 exclusion criteria: * known contraindications for sonovue * hematological bleeding status before experimental treatment: * hb \< 8g/dl, trc \< 80 x10 superscr 9/l, aptt˃ 45s, inr ˃ 1,5 * pregnancy

Keywords: contrast agent br sonovue ultrasonic therapy microbubbles
neoadjuvant chemotherapy in breast cancer

Conditions: Decision Support Systems, Clinical

Summary: this study compares two approaches of upfront chemotherapy in breast cancer.

a decision support system (dss) is an information system that supports business, medical, educational or organisational decision-making activities. dsss fuse human knowledge and technology to support and improve decision-making. the area of precision oncology that supports the treatment of breast cancer has not only seen an increase in the availability of different treatment choices but also genomic tools to support the decision-making process. cdsss have been available for use in clinical oncology practice for over a decade. however, there has been some criticism around the utility of cdss in personalised medicine decision-making of breast cancer, with these systems often viewed as aids better suited to support the 'average' patient's requirements rather than personalised treatment for the individual patient. the purpose of the current study is to evaluate an innovative cdss (medicbk) platform based on the comparison of multiple treatments simultaneously in making care decisions taking into account the individual characteristics of patients, i.e., based on personalized evidence-based medicine.

Eligibility criteria:
inclusion criteria: * histologically confirmed infiltrating breast cancer * stage ii or stage iii disease. nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or fdg-pet scan. * age ≥18 * eastern cooperative oncology group performance status ≤1 * adequate bone marrow function (anc \>1.5 x 109/l, platelets \>100 x 109/l) * adequate hepatic function (alat, asat and bilirubin \<2.5 times upper limit of normal) * adequate renal function (creatinine clearance \>50 ml/min) * lvef ≥50% measured by echocardiography or muga * absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * absence of any medical condition that would place the patient at unusual risk. * signed written informed consent exclusion criteria: * previous radiation therapy or chemotherapy * other malignancy except carcinoma in situ, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy. * current pregnancy or breastfeeding. women of childbearing potential must use adequate contraceptive protection * evidence of distant metastases. evaluation of the presence of distant metastases may include chest x-ray, liver ultrasound, isotope bone-scan, ct-scan of chest and abdomen and/or fdg-pet scan, according to local procedures. * evidence of bilateral infiltrating breast cancer. evaluation of the presence of bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or mri breast. * concurrent anti-cancer treatment or another investigational drug.
study of ketamine as an antidepressant in major depressive disorder

Conditions: Major Depressive Disorder

Summary: primary outcome measures: evaluate the changes in neuroimaging and biochemistry measures with ketamine treatment. secondary outcome measures: evaluate the effects of ketamine on depression symptoms, manic symptoms, global change in psychiatric symptoms, and suicidal ideation.


Eligibility criteria:
inclusion criteria:male patients, ages 18 to 65 years with a diagnosis of mdd, currently depressed or in a current major depressive episode of bd without psychotic features will be recruited into this substudy. current or past history of lack of response to one adequate antidepressant trial, operationally defined using the antidepressant treatment history form (athf); a failed adequate trial of ect would count as an adequate antidepressant trial. exclusion criteria:subjects with a history of dsm-iv drug or alcohol dependency or abuse (except for caffeine or nicotine dependence) within the preceding 3 months. in addition, subjects who currently are using oher antidepressant drugs in the 2 weeks prior to screen and must have a negative alcohol and drug urine test (except for prescribed benzodiazepines) urine test at screening. serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications. clinically significant abnormal laboratory tests. subjects with clinical hypothyroidism or hyperthyroidism. subjects with one or more seizures without a clear and resolved etiology. presence of metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip). subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk, or who have a madrs item 10 score

Keywords: depressive ketamine antidepressant
bakri balloon in placenta previa

Conditions: Bleeding; Placenta Previa

Summary: the bakri intrauterine balloon can achieve haemostasis in cases of postpartum haemorrhage, including haemorrhage associated with placenta previa by compressing the lower uterine segment.


Eligibility criteria:
inclusion criteria: 1. all women delivered and presented with primary atonic pph 2. women who accepted to participate exclusion criteria: 1. traumatic pph as excluded by examination under anesthesia. 2. with any suspected or clinical evidence of uterine infection 3. women diagnosed to have preeclampsia or eclampsia after delivery. 4. women who had dm during pregnancy 5. women with history of dvt or other thromboembolic complication 6. women with history of rheumatic heart disease. 7. women with coagulation defects.

Keywords: management
objective evaluation of paclitaxel/docetaxel-induced neuropathy in breast cancer patients

Conditions: Breast Cancer; Chemotherapy Induced Peripheral Neuropathy; Paclitaxel Induced Neuropathy

Summary: the purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (cipn) and cognitive impairment (cici).

the purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel or docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (cipn) and cognitive impairment (cici).

Eligibility criteria:
inclusion criteria: * women ages 18 to 70 with histologically confirmed clinically stage i-iii breast cancer who will receive weekly paclitaxel (80 mg/m2) or docetaxel (60-100mg/m2) chemotherapy as part of their routine care. exclusion criteria: * diabetes mellitus * prior history of neuropathy or symptoms of numbness or peripheral pain, or prior neurotoxic chemotherapy. * current symptoms of numbness and neuropathic pain * treatment for bipolar disease * treatment or concomitant use of common medications used to treat neuropathic pain, such as amitriptyline, gabapentin, pregabalin, duloxetine, for any indication * limited english that would preclude understanding and completion of the study questionnaires * pregnancy * life expectancy \<12 weeks * participation in other research studies either concurrent with or within 30 days prior to participation in this study may be an exclusion criteria

Keywords: neuropathy taxane docetaxel